Fuzeon (Enfuvirtide, T-20)

DO. SEE. HEAR. KNOW. Visit TheBody.com's 2008 World AIDS Day Center >>

BROWSE TOPICS IN HIV TREATMENT:

HIV Treatment: Home Page

Just Diagnosed

HIV Medications

First Steps to Treatment

HIV Drug Resistance

Switching or Stopping Treatment

Third Line/Rescue Treatment

Hepatitis C Coinfection

Women & Pregnancy

HIV Treatment for Children

Side Effects & Health Problems

Research & Experimental Drugs

HIV Treatment in the Developing World

The Basics | News | Research | First Person | Archive

Brand Name:	Fuzeon
Generic Name:	Enfuvirtide, T-20
Adult Single Dose:	Patients weighing more than 94 lbs (42.6 kg): 90 mg (1 mL) injected subcutaneously into the upper arm, thigh, or abdomen (twice a day)
Food & Liquid Restrictions:	None
Drug Class:	FI

The Basics

An Overview of Fuzeon (Enfuvirtide, T-20) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
Characteristics of Fusion and Integrase Inhibitors, and CCR5 Antagonists (PDF) (November 3, 2008)
An excerpt from the official U.S. HIV treatment guidelines for adults and adolescents. For the full guidelines, click here (PDF).
From AIDSinfo
Fuzeon (Enfuvirtide, T-20) (January/February 2008)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
Enfuvirtide (Fuzeon) (October 4, 2007)
To read PDF, click here
From AIDS InfoNet
Fuzeon (Enfuvirtide, T-20) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
Important Changes to Fuzeon Product Labeling (January 31, 2007)
From U.S. Food and Drug Administration
Patient Information About Fuzeon (Enfuvirtide, T-20) (PDF) (January 2007)
From Roche
Fuzeon (Enfuvirtide, T-20) Patient Product Information (PDF) (November 2006)
From Roche
T-20 (Enfuvirtide, Fuzeon) (August 15, 2006)
From AIDS Treatment Data Network
Fuzeon (Enfuvirtide) (May 2005)
To read PDF, click here
From The Center for AIDS
A Guide to Fuzeon: The First Fusion Inhibitor (January 2005)
To read PDF, click here
In A Guide to Fuzeon: The First Fusion Inhibitor, from The Body
Drug Interactions: Enfuvirtide (August 2004)
From Project Inform
Treatment Forum Discusses T-20 (January/February 2004)
Answers questions such as: Why is T-20 so expensive? Can it be taken by itself, or does it always have to be part of a combination? What about side effects?.
In Survival News, from AIDS Survival Project
Three New Drugs Approved by FDA (November/December 2003)
An overview of Fuzeon (enfuvirtide, T-20), Reyataz (atazanavir) and Emtriva (emtricitabine, FTC).
In Survival News, from AIDS Survival Project
Fuzeon -- A Review of the First Entry Inhibitor (October 2003)
A look at how entry inhibitors and Fuzeon work.
To read PDF, click here
From The Body
The Bottom Line on T-20 (Fuzeon), Atazanavir (Reyataz) and FTC (Emtriva) (October 2003)
Bare-bones highlights of three of this year's new HIV medications.
To read PDF, click here
In Project Inform Perspective, from Project Inform
FDA Approves Enfuvirtide (Fuzeon, ENF, T-20), the First HIV Fusion Inhibitor (May 2003)
A review of current knowledge regarding T-20 access and administration and optimal use guidelines, as well as a quick profile of the drug.
In Hopkins HIV Report
From Injections to Pricing: The Drawbacks of T-20 (April 2003)
In TAGline, from Treatment Action Group
Fuzeon (Enfuvirtide, T-20) Injection Instructions (PDF) (March 2003)
From Roche
Fuzeon (T-20) Approved in the U.S. (March 13, 2003)
First drug in a new class of HIV/AIDS treatments for HIV-infected adults and children with advanced HIV infection.
From U.S. Food and Drug Administration
New AIDS Drug Price Spurs Some Questions (March 13, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Long Path to Approval (March 2003)
A look back at Fuzeon's road from laboratory to pharmacy.
In GMHC Treatment Issues, from Gay Men's Health Crisis
Entry Inhibitors: T-20 (Winter 2002/2003)
In ACRIA Update, from AIDS Community Research Initiative of America

First Person

Beatriz Diaz: From Silence to Success (January 2005)
Beatriz Diaz, 49, learned the hard way that loving yourself is critical to committing to HIV treatment.
In A Guide to Fuzeon: The First Fusion Inhibitor, from The Body
Greg Braxton: A Long Journey to Recovery (January 2005)
With a 27-year history of drinking, using drugs and sleeping with hundreds of women, Greg Braxton's AIDS diagnosis in 1994 came as no surprise.
In A Guide to Fuzeon: The First Fusion Inhibitor, from The Body
Positive Empowerment: I Get Blessings, I Get Lesson (July/August 2003)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
The Constant Survival Battle and T-20 (Winter 2002/2003)
All of Matt Sharp's other meds had failed; then it was T-20's turn.
To read PDF, click here
In ACRIA Update, from AIDS Community Research Initiative of America
A T-20 Diary (March 2002)
Fred Gormley's first few days as part of the drug's clinical trial.
In GMHC Treatment Issues, from Gay Men's Health Crisis

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.